Magnesium Sulfate With Standard Combined Costoclavicular-Suprascapular Block for Pain Relief After Shoulder Arthroscopy.

Sponsor
Assiut University
Study ID
NCT07798115
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Postoperative Pain
  • Regional Anesthesia
  • Shoulder Arthroscopy

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Bupivacaine — DRUG
    "Bupivacaine 0.5% will be used as the local anesthetic for ultrasound-guided costoclavicular and suprascapular nerve blocks. A total of 25 mg (5 mL) will be administered for the costoclavicular nerve block and 50 mg (10 mL) for the suprascapular nerve block, for a total dose of 75 mg per participant."
  • Magnesium sulfate (MgSO4) — DRUG
    "Magnesium sulfate 150 mg (1.5 mL) will be used as an adjuvant to bupivacaine in each ultrasound-guided nerve block. A total of 300 mg (3 mL) of magnesium sulfate will be administered per participant, with 150 mg added to the costoclavicular nerve block and 150 mg added to the suprascapular nerve block."
  • Normal Saline (NS) — DRUG
    "Normal saline (0.9% sodium chloride) will be used as the control adjuvant, with 1.5 mL added to the local anesthetic solution for the costoclavicular nerve block and 1.5 mL added to the local anesthetic solution for the suprascapular nerve block, for a total volume of 3 mL per participant."
  • Costoclavicular Nerve Block — PROCEDURE
    "A single-shot ultrasound-guided costoclavicular nerve block will be performed using 5 mL of 0.5% bupivacaine (25 mg), with either 1.5 mL of magnesium sulfate (150 mg) or 1.5 mL of 0.9% normal saline, according to the assigned study group."
  • suprascapular nerve block — PROCEDURE
    "A single-shot ultrasound-guided suprascapular nerve block will be performed using 10 mL of 0.5% bupivacaine (50 mg), with either 1.5 mL of magnesium sulfate (150 mg) or 1.5 mL of 0.9% normal saline, according to the assigned study group."

Study Details

This study aims to evaluate whether adding magnesium sulfate to a combined costoclavicular and suprascapular nerve block improves postoperative pain control in patients undergoing shoulder arthroscopy. The study will compare pain management outcomes between patients receiving the nerve block with magnesium sulfate and those receiving the nerve block without magnesium sulfate. The main outcome will be the time to first rescue analgesia after surgery.

Key Dates

First listed
Sep 1, 2026
Start date
Sep 1, 2026
Status verified
Aug 2026
Primary completion
Dec 30, 2027
Completion
Mar 30, 2028

Study Design

Enrollment
84 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Costoclavicular-Suprascapular Block with Normal Saline
    Participants will receive a single-shot ultrasound-guided costoclavicular brachial plexus block with 5 mL of 0.5% bupivacaine (25 mg) combined with 1.5 mL of 0.9% normal saline, followed by an ultrasound-guided suprascapular nerve block with 10 mL of 0.5% bupivacaine (50 mg) combined with 1.5 mL of 0.9% normal saline.
  • Experimental: Costoclavicular-Suprascapular Block with regional Magnesium Sulfate
    Participants will receive a single-shot ultrasound-guided costoclavicular brachial plexus block with 5 mL of 0.5% bupivacaine (25 mg) combined with 1.5 mL of magnesium sulfate (150 mg), followed by an ultrasound-guided suprascapular nerve block with 10 mL of 0.5% bupivacaine (50 mg) combined with 1.5 mL of magnesium sulfate (150 mg).
  • Experimental: Costoclavicular-Suprascapular Block with Intravenous Magnesium Sulfate
    Participants will receive a single-shot ultrasound-guided costoclavicular brachial plexus block with 5 mL of 0.5% bupivacaine (25 mg) combined with 1.5 mL of 0.9% normal saline, followed by an ultrasound-guided suprascapular nerve block with 10 mL of 0.5% bupivacaine (50 mg) combined with 1.5 mL of 0.9% normal saline. Following the nerve blocks, participants will receive 150 mg of magnesium sulfate diluted in 100 mL of 0.9% normal saline administered intravenously.

Primary Outcome Measure

Time to first rescue analgesia after discharge from PACU. [ Time Frame: From discharge from PACU until 24 hours postoperatively. ]

Central Contacts

Related Studies